NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it filed a certificate of amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-50 reverse stock split of its common stock.
What is the price targets for Sellas life sciences group (Sellas)?
Apr 01, 2022 · SELLAS Life Sciences Group's stock was trading at $2.14 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SLS stock has increased by 62.6% and is now trading at $3.48.
What is the upside for Sellas life sciences group (Sellas) stock?
Nov 06, 2019 · NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it filed a certificate of amendment to its amended and restated …
Should you diversify your Sellas life sciences stock?
About Sellas. Management. Our leadership team is committed to addressing compelling medical needs. ... Historical Stock Quote. Investment Calculator. Investment amount ($) Start date. End date. Compare to: S&P 500. Nasdaq 100. Dow 30. Other. Reinvest Dividends. Calculate. Contact United States Of America.
How risky is Sellas Life Sciences Group’s balance sheet?
Who owns Sellas life sciences?
Top 10 Owners of Sellas Life Sciences Group IncStockholderStakeShares ownedThe Vanguard Group, Inc.4.06%645,651BlackRock Fund Advisors1.58%251,643Geode Capital Management LLC0.84%133,801Equitable Advisors LLC0.64%102,0006 more rows
Is SLS a good stock to buy?
SELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Will SLS go up?
Given the current short-term trend, the stock is expected to rise 16.87% during the next 3 months and, with a 90% probability hold a price between $6.13 and $8.43 at the end of this 3-month period.
What is the current status of the SLS?
As of March 2022, the first launch is scheduled for no earlier than June 2022, pending the success of a wet dress rehearsal test after the Axiom-1 Launch.
Is SELLAS Life Sciences Group a buy right now?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last twelve months. There are currently...
How has SELLAS Life Sciences Group's stock price been impacted by Coronavirus?
SELLAS Life Sciences Group's stock was trading at $2.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health...
When is SELLAS Life Sciences Group's next earnings date?
SELLAS Life Sciences Group is scheduled to release its next quarterly earnings announcement on Tuesday, March 22nd 2022. View our earnings forecas...
How were SELLAS Life Sciences Group's earnings last quarter?
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.45) earni...
When did SELLAS Life Sciences Group's stock split? How did SELLAS Life Sciences Group's stock split work?
SELLAS Life Sciences Group shares reverse split on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019....
What price target have analysts set for SLS?
4 analysts have issued 1-year price objectives for SELLAS Life Sciences Group's shares. Their forecasts range from $16.00 to $21.00. On average, th...
Who are SELLAS Life Sciences Group's key executives?
SELLAS Life Sciences Group's management team includes the following people: Angelos M. Stergiou , President, Chief Executive Officer & Director J...
Who are some of SELLAS Life Sciences Group's key competitors?
Some companies that are related to SELLAS Life Sciences Group include Enochian Biosciences (ENOB) , Akebia Therapeutics (AKBA) , Avadel Pharmace...
What is SELLAS Life Sciences Group's stock symbol?
SELLAS Life Sciences Group trades on the NASDAQ under the ticker symbol "SLS."
What is the SLS call?
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET. The call will be facilitated by SELLAS’ President & CEO, Angelos Stergiou, MD, ScD. h.c., who will provide a corporate update. Event:Shareholder Update CallDate:Thursday, June 3, 2021Time:8:30 a.m. ETLive Call:1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)Webcast:https://www.sellaslifesciences.com/investors/events-and-presentations For interested individuals unable to join the conference call, a replay of the call will be available through June 17, 2021, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13719788. The online archive of the webcast will be available at https://www.sellaslifesciences.com/investors/events-and-presentations after the conclusion of the call. About SELLAS Life Sciences Group, Inc. SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care. For more information on SELLAS, please visit www.sellaslifesciences.com. Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various important factors. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. For more information, please contact: Investor Contacts Valter Pinto / Allison Soss KCSA Strategic Communications Email: [email protected] Phone: 914.907.2675 / 215.272.2707 Media Contacts Caitlin Kasunich / Raquel Cona KCSA Strategic Communications Email: [email protected] Phone: 212.896.1241 / 212.896.1276
What is GPS in combination with?
The allowed claims of the patent application cover the use of GPS in combination with any antibody checkpoint inhibitor that blocks or inhibits programmed cell death protein 1 (PD-1), such as nivolumab and pembrolizumab.
What is NPS in SELLAS?
SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following the standard of care.
How much is R&D 2020?
R&D Expenses: Research and development expenses for the year ended December 31, 2020 were $9.3 million, as compared to $7.3 million for the year ended December 31, 2019. The increase was primarily due to clinical trial expenses incurred in connection with the initiation of the Phase 3 REGAL study in 2020.
What is the second product candidate for Sellas?
SELLAS’ second product candidate, NPS, is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care.